An injectable superior depot of Telratolimod inhibits post-surgical tumor recurrence and distant metastases

Liu, Yubo; Li, Chang; Xia, Hong; Bi, Jian; Guan, Rou; Du, Xiaoxiao; Zhang, Haotian; Zhang, He; Wang, Yongjun; Liu, Hongzhuo

doi:10.1016/j.actbio.2022.01.013

Cited by 9 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD8 + T cells are also known as cytotoxic T lymphocytes or CTLs and play an important role in anti-tumor. Once CD8 + T cells recognize tumor antigens and are activated, it destroys the target cells directly (Feng et al., 2021 ; Li et al., 2021 ; Liu et al., 2022 ). The proportion of CD4 + and CD8 + T cells in the spleen of tumor bearing mice was also analyzed by flow cytometry, and the results were displayed in Figure 8c,d .…”

Section: Resultsmentioning

confidence: 99%

Biomimetic virus-like mesoporous silica nanoparticles improved cellular internalization for co-delivery of antigen and agonist to enhance Tumor immunotherapy

et al. 2023

Self Cite

View full text Add to dashboard Cite

Nanocarrier antigen-drug delivery system interacts specifically with immune cells and provides intelligent delivery modes to improve antigen delivery efficiency and facilitate immune progression. However, these nanoparticles often have weak adhesion to cells, followed by insufficient cell absorption, leading to a failed immune response. Inspired by the structure and function of viruses, virus-like mesoporous silica nanoparticles (VMSNs) were prepared by simulating the surface structure, centripetal-radialized spike structure and rough surface topology of the virus and co-acted with the toll-like receptor 7/8 agonist imiquimod (IMQ) and antigens oocyte albumin (OVA). Compared to the conventional spherical mesoporous silica nanoparticles (MSNs), VMSNs which was proven to be biocompatible in both cellular and in vivo level, had higher cell invasion ability and unique endocytosis pathway that was released from lysosomes and promoted antigen cross-expression. Furthermore, VMSNs effectively inhibited B16-OVA tumor growth by activating DCs maturation and increasing the proportion of CD8 + T cells. This work demonstrated that virus-like mesoporous silica nanoparticles co-supply OVA and IMQ, could induce potent tumor immune responses and inhibit tumor growth as a consequence of the surface spike structure induces a robust cellular immune response, and undoubtedly provided a good basis for further optimizing the nanovaccine delivery system.

show abstract

Section: Resultsmentioning

confidence: 99%

Biomimetic virus-like mesoporous silica nanoparticles improved cellular internalization for co-delivery of antigen and agonist to enhance Tumor immunotherapy

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, Liu and coworkers designed an injectable phase transition gel (PGE) platform, a biodegradable liquid crystal composed of phospholipids with hydrophobic long chains (Figure 8B). [ 71 ] Telratolimod (Tel) is a TLR 7/8 agonist recognized for its immunostimulatory properties. [ 103 ] When loaded with Tel, the Tel@PGE formulation effectively inhibited MDSCs in tumor‐bearing mice in an in vivo setting.…”

Section: Recent Advances In Nanomedicine Targeting Mdscsmentioning

confidence: 99%

“…B) Schematic illustration depicting how Tel@PGE reprograms the immunosuppressive TME, fostering a systemic antitumor immune response to thwart postoperative tumor recurrence and metastasis. Reproduced with permission [71]. Copyright 2022, Elsevier.…”

mentioning

confidence: 99%

Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity

Yang,

Sun

2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Cancer immunotherapy, a field within immunology that aims to enhance the host's anti‐cancer immune response, frequently encounters challenges associated with suboptimal response rates. The presence of myeloid‐derived suppressor cells (MDSCs), crucial constituents of the tumor microenvironment (TME), exacerbates this issue by fostering immunosuppression and impeding T cell differentiation and maturation. Consequently, targeting MDSCs has emerged as crucial for immunotherapy aimed at enhancing anti‐tumor responses. The development of nanomedicines specifically designed to target MDSCs aims to improve the effectiveness of immunotherapy by transforming immunosuppressive tumors into ones more responsive to immune intervention. This review provides a detailed overview of MDSCs in the TME and current strategies targeting these cells. We also highlight the benefits of nanoparticle‐assisted drug delivery systems, including design flexibility, efficient drug loading, and protection against enzymatic degradation. It summarizes advances in nanomedicine targeting MDSCs, covering enhanced treatment efficacy, safety, and modulation of the TME, laying the groundwork for more potent cancer immunotherapy.This article is protected by copyright. All rights reserved

show abstract

“…Moreover, a sustained release of an immunoadjuvant is crucial for the awakening of immune responses. [29][30][31] So, we tried to achieve a sustained release of R837 in this study taking advantage of a smart polymeric system.…”

Section: Introductionmentioning

confidence: 99%

Unified Therapeutic‐Prophylactic Vaccine Demonstrated with a Postoperative Filler Gel to Prevent Tumor Recurrence and Metastasis

Cao

Guo

Cai

et al. 2022

Adv Funct Materials

View full text Add to dashboard Cite

Although surgical resection is currently the first choice of clinical treatment for most solid tumors, postoperative cancer recurrence and metastasis are the main causes of mortality. Herein, the authors aim to enable immunotherapy consistent with surgery. To this end, the term “therapeutic‐prophylactic vaccine (TPV)” is suggested, and a TPV‐gel is developed as a filler after resection of ≈90% tumor to eradicate residue tumor (therapeutic) and prevent recurrence and metastasis (prophylactic). The TPV‐gel is made of the matrix of blends of two poly(d,l‐lactide‐co‐glycolide)‐b‐poly(ethylene glycol)‐b‐poly(d,l‐lactide‐co‐glycolide) block copolymers and the bioactive substances of inorganic calcium salt and organic R837. The aqueous system of polymeric block blends undergoes a sol‐gel transition upon heating and thus leads to an injectable hydrogel filling the resection site; loading of CaCl2 and CaCO3 results in the release of calcium ions out of the TPV‐gel, which induces immunogenic cell death of the residual tumor cells; R837, an immune adjuvant, is dispersed in the TPV‐gel as microcrystal and can be released to awaken immune responses. The therapeutic and prophylactic efficacy of this TPV‐gel is confirmed in vitro and in vivo using a postoperative breast 4T1 mice model.

show abstract

An injectable superior depot of Telratolimod inhibits post-surgical tumor recurrence and distant metastases

Cited by 9 publications

References 28 publications

Biomimetic virus-like mesoporous silica nanoparticles improved cellular internalization for co-delivery of antigen and agonist to enhance Tumor immunotherapy

Biomimetic virus-like mesoporous silica nanoparticles improved cellular internalization for co-delivery of antigen and agonist to enhance Tumor immunotherapy

Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity

Unified Therapeutic‐Prophylactic Vaccine Demonstrated with a Postoperative Filler Gel to Prevent Tumor Recurrence and Metastasis

Contact Info

Product

Resources

About